Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
一项评价CG-BM1异体人骨髓间充质干细胞注射液治疗慢加急性肝衰竭患者的安全性、耐受性和初步有效性临床试验
[Translation] A clinical trial evaluating the safety, tolerability and preliminary efficacy of CG-BM1 allogeneic human bone marrow mesenchymal stem cell injection in the treatment of patients with acute-on-chronic liver failure
主要目的:评价CG-BM1治疗成人ACLF患者的安全性和耐受性,确定临床用药的安全范围。次要目的:观察CG-BM1治疗成人ACLF患者的初步有效性,为后续临床试验方案设计提供依据。
[Translation] Main purpose: To evaluate the safety and tolerability of CG-BM1 in the treatment of adult patients with ACLF, and to determine the safety range of clinical medication. Secondary purpose: To observe the preliminary effectiveness of CG-BM1 in the treatment of adult patients with ACLF, and to provide a basis for the design of follow-up clinical trials.
一项评价异体人骨髓间充质干细胞(CG-BM1)注射液治疗中、重度成人急性呼吸窘迫综合征患者的安全性、耐受性和初步有效性的Ⅰ期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and preliminary efficacy of allogeneic human bone marrow mesenchymal stem cell (CG-BM1) injection in the treatment of moderate and severe adult patients with acute respiratory distress syndrome
主要目的:评价CG-BM1治疗感染引起的中、重度成人ARDS患者的安全性和耐受性。
次要目的:评价CG-BM1治疗感染引起的中、重度成人ARDS患者的初步有效性。
[Translation] MAIN OBJECTIVE: To evaluate the safety and tolerability of CG-BM1 in the treatment of adult patients with moderate to severe ARDS caused by infection.
Secondary objective: To evaluate the preliminary efficacy of CG-BM1 in the treatment of moderate to severe adult ARDS caused by infection.
Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe cases, it was found that aberrant pathogenic T cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm.Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with COVID-19.
100 Clinical Results associated with Guangzhou Cellgenes Biotechnology Co.,Ltd
0 Patents (Medical) associated with Guangzhou Cellgenes Biotechnology Co.,Ltd
100 Deals associated with Guangzhou Cellgenes Biotechnology Co.,Ltd
100 Translational Medicine associated with Guangzhou Cellgenes Biotechnology Co.,Ltd